We are live on ! Find out more
KYTH

KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH

Delisted

KYTH was delisted on the 30th of September, 2015.

83 hedge funds and large institutions have $453M invested in KYTHERA BIOPHARMACEUTICALS, INC COM in 2013 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 34 increasing their positions, 14 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

450% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 4

143% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 14

96% more capital invested

Capital invested by funds: $231M → $453M (+$222M)

28% more funds holding

Funds holding: 6583 (+18)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

Holders
83
Holders Change
+18
Holders Change %
+27.69%
% of All Funds
2.69%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
22
Increased
34
Reduced
14
Closed
4
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$111M +$7.66M +256,235 +12%
Jennison Associates
2
Jennison Associates
New York
$53.9M -$342K -11,446 -1%
PHS
3
PFM Health Sciences
California
$35M -$10.4M -348,079 -31%
Massachusetts Financial Services
4
Massachusetts Financial Services
Massachusetts
$31.1M +$6.11M +204,436 +43%
Adage Capital Partners
5
Adage Capital Partners
Massachusetts
$22.8M +$2.24M +75,000 +18%
WRF
6
Waddell & Reed Financial
Kansas
$19.4M +$12.7M +424,318 New
Capital World Investors
7
Capital World Investors
California
$14.9M
PAI
8
Palo Alto Investors
California
$14.5M +$6.97M +232,912 +270%
BFA
9
BlackRock Fund Advisors
California
$13.1M +$996K +33,305 +13%
BBA
10
Baker Bros. Advisors
New York
$12.1M +$2.99M +100,000 +61%
CCI
11
Columbus Circle Investors
$10.7M +$7.01M +234,269 New
RG
12
Redmile Group
California
$10.4M +$3.53M +118,100 +107%
Vanguard Group
13
Vanguard Group
Pennsylvania
$8.85M +$1.1M +36,836 +23%
Millennium Management
14
Millennium Management
New York
$7.46M +$2.65M +88,482 +118%
Northern Trust
15
Northern Trust
Illinois
$6.46M +$1.46M +48,866 +53%
State Street
16
State Street
Massachusetts
$5.94M +$1.65M +55,157 +74%
BIT
17
BlackRock Institutional Trust
California
$5.55M +$79.6K +2,663 +2%
Allianz Asset Management
18
Allianz Asset Management
Germany
$5.37M
AGA
19
Altrinsic Global Advisors
Connecticut
$5.16M
AAM
20
Aureus Asset Management
Massachusetts
$4.21M +$2.76M +92,350 New
Bank of New York Mellon
21
Bank of New York Mellon
New York
$4.13M -$147K -4,926 -5%
AC
22
Ascend Capital
California
$3.77M -$769K -25,707 -24%
IA
23
Investor AB
Sweden
$3.54M -$2.84M -95,000 -54%
BCM
24
BBT Capital Management
Texas
$2.96M -$4.82M -161,243 -71%
OAM
25
Oxford Asset Management
United Kingdom
$2.76M +$1.8M +60,328 New

KYTH Hedge Fund Activity: Q3 2013 in Review

83 of the 3,085 institutional investors tracked by Wall St. Rank reported a position in KYTHERA BIOPHARMACEUTICALS, INC COM (KYTH) for Q3 2013, worth a combined $453M — up 96% from $231M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new KYTH positions and 4 closed out — a net gain of 18 holders — while 34 added to existing stakes and 14 trimmed.

The largest buyer was Waddell & Reed Financial, opening a new position worth an estimated $12.7M. The largest seller was PFM Health Sciences, cutting an estimated $10.4M.

  • 83 institutional investors held KYTHERA BIOPHARMACEUTICALS, INC COM (KYTH) as of Q3 2013, up from 65 in Q2 2013.
  • Funds reported $453M of KYTHERA BIOPHARMACEUTICALS, INC COM stock for Q3 2013, up 96% quarter-over-quarter.
  • 22 funds opened new KYTHERA BIOPHARMACEUTICALS, INC COM positions in Q3 2013 and 4 closed out, a net change of +18 holders.
  • The largest KYTHERA BIOPHARMACEUTICALS, INC COM buyer in Q3 2013 was Waddell & Reed Financial, an estimated $12.7M added.
  • The largest KYTHERA BIOPHARMACEUTICALS, INC COM seller in Q3 2013 was PFM Health Sciences, an estimated $10.4M sold.

Based on aggregated 13F filings for Q3 2013.